金沙中國有限公司(01928.HK)建議發行優先票據 發行金額未定
格隆匯6月2日丨金沙中國有限公司(01928.HK)發佈公告,公司建議向專業投資者提呈發售票據。建議提呈發售票據的完成取決於市況及投資者的意向。Barclays Capital Inc.、BofA Securities, Inc.及Goldman Sachs & Co. LLC已獲委任為聯席賬簿管理人。
票據的定價將透過由聯席賬簿管理人所進行的累計投標程序釐定。票據一經發行須於到期日償還,除非根據其條款獲提前贖回或購回。
於該公告日期,票據的本金總額、條款及條件尚未釐定。於落實票據的條款後,預期初始買家與公司將訂立購買協議。倘簽訂具約束力協議,則公司將就建議提呈發售票據另作公告。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.